Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 10, 2007
Last updated: January 9, 2014
Last verified: August 2009